S'abonner

Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies - 03/04/25

Doi : 10.1016/j.clinre.2025.102584 
Parag Jain a, , Akanksha Jain b, Rohitas Deshmukh c, Pradeep Samal d, Trilochan Satapathy e,  Ajazuddin a
a Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Bhilai, C.G., India, 490024 
b Department of Biotechnology, Bharti University, Durg, C.G., India 
c Institute of Pharmaceutical Research, GLA University, Mathura, India, 281406 
d Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, C.G., India 
e Department of Pharmacy, Columbia Institute of Pharmaceutical Sciences, Raipur, C.G., India, 493111 

Corresponding author at: Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Bhilai, C.G., India – 490024.Department of Pharmacology, Rungta College of Pharmaceutical Sciences and ResearchBhilaiC.G.490024India

Highlights

Metabolic dysfunction-associated steatotic liver disease (MASLD) includes the inflammatory subtype metabolic dysfunction-associated steatohepatitis.
Insulin resistance, obesity, and dyslipidaemia produce MASLD in over 30 % of adults.
Hepatic inflammation and fibrosis progress from MASLD to MASH, eventually leading to cirrhosis, hepatocellular carcinoma, cardiovascular disease, chronic kidney disease and sarcopenia.
Pioglitazone, an SGLT-2 inhibitor, and GLP-1 receptor agonists have shown encouraging results in the treatment of metabolic dysfunction.
Lifestyle modification is considered as the main management of MASLD currently.

Le texte complet de cet article est disponible en PDF.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), which includes the inflammatory subtype metabolic dysfunction-associated steatohepatitis, is a prominent cause of chronic liver disease with systemic effects. Insulin resistance, obesity, and dyslipidaemia produce MASLD in over 30 % of adults. It is a global health issue. From MASLD to MASH, hepatic inflammation and fibrosis grow, leading to cirrhosis, hepatocellular cancer, and extrahepatic complications such CVD, CKD, and sarcopenia. Effects of MASLD to MASH are mediated through mechanisms that include inflammation, oxidative stress, dysbiosis, and predisposition through genetic makeup. Advances in diagnostic nomenclature in the past few years have moved the emphasis away from NAFLD to MASLD, focusing on the metabolic etiology and away from the stigma of an alcoholic-related condition. Epidemiological data show a large geographical variability and increasing prevalence in younger populations, particularly in regions with high carbohydrate-rich diets and central adiposity. Lifestyle modification is considered as the main management of MASLD currently. This may include dietary intervention, exercise, and weight loss management. Pharmaceutical management is primarily aimed at metabolic dysfunction with promising findings for GLP-1 receptor agonists, pioglitazone and SGLT-2 inhibitors, which can correct both hepatic and systemic outcome. However, it still depends on well-integrated multidisciplinary care models by considering complex relationships between MASLD and its effects on extrahepatic organs. Determining complications at an early stage; developing precision medicine strategies; exploring new therapeutic targets will represent crucial factors in improving their outcomes. This review discuss the systemic nature of MASLD and calls for multiple collaborations to reduce its far-reaching health impacts and our quest for understanding its pathological mechanisms. Thus, collective efforts that are required to address MASLD are under the public health, clinical care, and research angles toward effectively containing its rapidly increasing burden.

Le texte complet de cet article est disponible en PDF.

Keywords : MASLD, NASH, Diabetes, Kidney disease, Steatosis, Adiposity


Plan


© 2025  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 49 - N° 6

Article 102584- juin 2025 Retour au numéro
Article précédent Article précédent
  • Research progress on the regulatory role of different cell death pathways in metabolic-dysfunction-associated steatotic liver disease
  • Congyue Zhang, Mengjiao Sun, Yuanjian Ding, Xiwei Yuan, Jingyi Lu, Yuemin Nan
| Article suivant Article suivant
  • Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
  • Parag Jain, Akanksha Jain, Rohitas Deshmukh, Pradeep Samal, Trilochan Satapathy

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.